Diabetic Neuropathy Research and Withings Technologies Highlighted at The American Diabetes Association’s 84th Scientific Sessions

A number of major new studies and advancements related to screening for diabetic peripheral neuropathy (DPN) were presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando.

The headliner was a longitudinal study – “Combined DPNCheck and SUDOSCAN as a Screening Tool for DPN—The Sheffield Prospective Study” – presented by Dr. Mohummad Shaan Goonoo of Sheffield Teaching Hospitals and NHS Foundation Trust. Dr. Goonoo presented data that evaluated the ability of point-of-care-devices (POCDs) to accurately diagnose DPN. The POCDs used were Withings SUDOSCAN, incorporating our Electrochemical Skin Conductance (ESC) technology, and DPNCheck, a handheld device which measures sural nerve conduction-velocity/amplitude.

In the study, 229 participants with diabetes who attended a one-stop microvascular screening service were re-called for follow-up evaluation at 7 years. Baseline assessments were repeated including: Toronto Clinical Neuropathy Score, 10g monofilament, SUDOSCAN and DPNCheck, and nerve conduction studies.

The study demonstrated significantly increased risk of incident clinical DPN in patients with abnormal baseline POCDs (microalbuminuria equivalent). The findings supported the use of POCDs as a screening tool for early DPN diagnosis, when cardio-metabolic control may halt the progressive neuropathic process.

Improving DFU Risk Stratification

A separate study was presented in a poster session entitled “Improving Diabetic Foot Ulcer (DFU) Management with Electrochemical Skin Conductance (ESC)”. The study, which also used Withings ESC technology, assessed the association between ESC measures and DFU risk stratification scores in 2157 diabetic patients from four French hospitals.

Interested in partnering with us?

Contact Us